Prespecified pooled analysis of the STEP-HFpEF program shows once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
In the FLOW randomised controlled trial, weekly semaglutide reduced major kidney disease events and cardiovascular death in patients with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
A prespecified secondary analysis of the STEP-HFpEF programme found that semaglutide 2.4 mg lowered NT-proBNP and produced larger health-status gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
A post hoc analysis testing whether machine-learning digital pathology reproduces pathologist scoring of liver biopsies in a phase II semaglutide NASH trial. PICO summary and expert commentary.
A prespecified FLOW subgroup analysis tested whether semaglutide’s kidney and cardiovascular benefit held with or without baseline SGLT2 inhibitor use in type 2 diabetes and CKD. PICO summary and expert commentary.
Prespecified secondary analysis of the pooled STEP-HFpEF trials finds semaglutide 2.4 mg improves heart failure symptoms similarly in women and men, with greater weight loss in women. PICO summary and expert commentary.
A phase 1 trial characterising oral semaglutide pharmacokinetics, pharmacodynamics and tolerability in 32 healthy Chinese adults. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial shows once-weekly semaglutide produced a placebo-subtracted weight reduction of 10.2% sustained to 208 weeks in adults with cardiovascular disease and overweight or obesity but without diabetes. PICO summary and expert commentary.
A pre-specified analysis of the SELECT trial assessing whether once-weekly semaglutide 2.4 mg improves kidney outcomes in adults with overweight or obesity and cardiovascular disease, without diabetes. PICO summary and expert commentary.
A prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials showing that once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.